雌激素增加良性乳腺疾病发病的风险，
Estrogen raises risk of benign breast diseaseCHICAGO (Reuters) - Women who took a commonly prescribed hormone replacement therapy pill had double the risk of developing benign proliferative breast disease, which may raise the risk of breast cancer, U.S. researchers said on Tuesday.
芝加哥（路透社） -美国研究人员周二说，服用激素替代疗法女性有可能发展成良性增生性乳腺疾病比未服用的多一倍，这些良性增生性乳腺疾病可能会增加妇女患乳腺癌的危险。
The study, published in the Journal of the National Cancer Institute, is one of dozens trying to paint a clearer picture of what risks might come from taking hormone replacement therapy, or HRT, to treat menopause symptoms.
这一研究结果最近发表在美国国家癌症研究所杂志上，是数十项研究试图搞清楚使用激素替代疗法治疗更年期症状可能的存在的风险。
Dr. Thomas Rohan of the Albert Einstein College of Medicine in New York and colleagues aimed to see if taking the Wyeth drug Premarin, a form of estrogen derived from the urine of pregnant mares, could raise the risk of these types of non-cancerous breast disease.
来自纽约艾伯特爱因斯坦医学院的Thomas Rohan博士和他的同事的研究目的是看看惠氏药物倍美力，从怀孕母马尿中的提取的一种形式的雌激素，是否可以提高那些的非癌变类型乳腺疾病的风险。
They looked at 10,739 women past menopause who had taken part in a highly publicized study known as the Women's Health Initiative or WHI. The women in this part of the study had taken either estrogen alone or placebo and were followed for almost seven years.
他们观察了10739名更年期妇女，这些妇女过去曾参与了称为妇女的健康倡议或WHI研究，这研究曾引起了公众的高度关注。在这部分的研究妇女服用了单独的雌激素或安慰剂，并随访近七年。
While the larger WHI study found that women who took combination hormone replacement therapy had a higher risk of heart attack, stroke, breast cancer and other serious conditions, this estrogen-only part of the study in women who had a hysterectomies did not show an increase in breast cancer risk.
而大量的WHI研究发现，行雌、孕激素结合替代疗法的妇女有心脏病发作，中风，乳癌及其他严重的情况的高风险发病率，在进行了子宫切除并只服用雌激素妇女并没有显示增加患乳腺癌的风险。
Rohan's team identified 232 women from this estrogen-only part of the study who had biopsies for what turned out to be non-cancerous breast disease and who had taken either estrogen alone or a placebo.
Rohan的研究小组对只服用雌激素232名妇女进行乳腺活检为最终被证明是非癌变乳腺疾病，并也对无论是曾服用单独的雌激素或安慰剂进行了同样的研究。
ALREADY CAREFUL
已经仔细的研究
They found 155 cases of non-cancerous proliferative breast disease in women who had taken estrogen, compared with 77 in the placebo group.
他们发现，曾服用雌激素妇女有155例非肿瘤增生性乳腺疾病，相比使用安慰剂的一组的妇女只有77个。
While the study sheds more light on the risks linked with taking estrogen therapy, Rohan thinks it will not change practices much because women must already be mindful of the risks of HRT.
而研究进一步的明确了与雌激素治疗相关的风险，罗汉认为，但它不会过多的改变激素替代治疗的医疗行为，因为只要妇女必须已经意识到激素替代治疗的风险。
\"Each and every person who is a candidate for taking hormone therapy really needs to weigh the risks and benefits. You might say, this is one additional risk,\" Rohan said in a telephone interview.
\"用激素替代疗法的每个人确实需要权衡激素替代疗法风险和益处，你也许会说，这是一个额外的风险， \"罗汉在电话采访中说。
But Dr. Hugh Taylor of the Yale University School of Medicine who had seen the study, said the increase in benign proliferative breast disease may simply reflect the fact that breast tissue responds to estrogen.
不过耶鲁大学医学院专家Hugh Taylor博士看到了这项研究后认为所谓的增加的良性增生性乳腺疾病的可能只是反映了这样一个乳房组织受雌激素响应事实而已。
\"It sounds scarier than it is,\" Taylor said in a telephone interview. \"Breasts are supposed to grow in response to estrogen. That is what a normal healthy breast does,\" he said.
\"它听起来比它的真实情况可怕的， \" Taylor在电话采访中说。 \"乳房受雌激素影响会增大，一个正常健康的乳房都是那样的， \"他说。
Wyeth said in a statement the study reflected only a small subset of the more than 10,000-patient study, which found no increased risk of breast cancer.
Wyeth在这项研究声明中说，这仅仅反映的是一万多名病人的研究，这项研究并没有发现增加妇女患乳腺癌的危险。
Rohan said it may be that women in the study had not been followed long enough for breast cancer to develop, but it was not clear from the study whether these non-cancerous growths would develop into cancer.
Rohan说，也许是因为在研究中妇女没有随访到能够发展未乳腺癌的阶段，但从研究中目前尚不清楚，是否这些非肿瘤的生长会发展成癌症。
The Women's Health Initiative only looked at women taking Premarin-based products, and most were on average 10 years past menopause. Other estrogen therapies are now available at lower doses and some studies have suggested that women who start HRT when they are younger, right around menopause, have fewer health risks from HRT
妇女健康倡议协会只调查了使用倍美力为基础产品的女性，而且大多数是平均更年期过去10年的妇女。现已用的较低剂量其他雌激素疗法和一些有研究显示，使用激素替代治疗年轻的女性和近围绝经期妇女，由激素替代治疗所引起的健康风险较少。
页:
[1]